Rep. Lisa C. McClain Purchases Shares of ImmunityBio, Inc. (NASDAQ:IBRX)

Representative Lisa C. McClain (Republican-Michigan) recently bought shares of ImmunityBio, Inc. (NASDAQ:IBRX). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in ImmunityBio stock on September 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K (HANTZ) > SCHWAB 824” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 9/30/2026.
• Sold $15,001 – $50,000 in shares of Seagate Technology (NASDAQ:STX) on 9/30/2026.
• Purchased $1,001 – $15,000 in shares of Caterpillar (NYSE:CAT) on 9/28/2026.
• Purchased $1,001 – $15,000 in shares of ImmunityBio (NASDAQ:IBRX) on 9/28/2026.
• Purchased $15,001 – $50,000 in shares of Olin (NYSE:OLN) on 9/14/2026.
• Purchased $1,001 – $15,000 in shares of Novagold Resources (NYSEAMERICAN:NG) on 9/14/2026.
• Purchased $15,001 – $50,000 in shares of Transocean (NYSE:RIG) on 9/14/2026.
• Purchased $15,001 – $50,000 in shares of CACI International (NYSE:CACI) on 9/14/2026.

ImmunityBio Price Performance

Shares of NASDAQ:IBRX opened at $9.80 on Wednesday. The company’s 50 day simple moving average is $8.43 and its 200 day simple moving average is $7.92. The stock has a market capitalization of $10.39 billion, a price-to-earnings ratio of -10.10 and a beta of 0.02. ImmunityBio, Inc. has a 1 year low of $1.95 and a 1 year high of $12.43.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The business had revenue of $51.24 million for the quarter, compared to analyst estimates of $49.70 million. As a group, analysts anticipate that ImmunityBio, Inc. will post -0.44 EPS for the current fiscal year.

Analysts Set New Price Targets

IBRX has been the topic of several recent analyst reports. Jefferies Financial Group upgraded ImmunityBio to a “strong-buy” rating in a research note on Friday, September 25th. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, October 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, ImmunityBio presently has an average rating of “Moderate Buy” and a consensus price target of $14.20.

Hedge Funds Weigh In On ImmunityBio

A number of institutional investors have recently added to or reduced their stakes in the stock. Markowski Investments bought a new stake in shares of ImmunityBio during the second quarter worth about $29,000. GAMMA Investing LLC raised its holdings in ImmunityBio by 262.2% in the 3rd quarter. GAMMA Investing LLC now owns 3,807 shares of the company’s stock valued at $36,000 after buying an additional 2,756 shares during the last quarter. Hollencrest Capital Management bought a new position in ImmunityBio in the 2nd quarter valued at approximately $44,000. Western Wealth Management LLC acquired a new stake in ImmunityBio during the 1st quarter worth approximately $44,000. Finally, Geneos Wealth Management Inc. boosted its position in ImmunityBio by 579.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company’s stock worth $44,000 after buying an additional 4,907 shares during the period. 8.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Cheryl Cohen sold 81,056 shares of the firm’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total transaction of $851,088.00. Following the completion of the transaction, the director owned 100,309 shares of the company’s stock, valued at approximately $1,053,244.50. This trade represents a 44.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the firm’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $10.75, for a total transaction of $268,750.00. Following the transaction, the director directly owned 2,777,788 shares of the company’s stock, valued at $29,861,221. The trade was a 0.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 66.10% of the company’s stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About ImmunityBio

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator.